Five Advanced Therapeutics to Watch in 2H 2025
The CGTLive® team highlights 5 therapeutics that are nearing major decisions by the FDA.
In recent years, the FDA has continued to ramp up its activities around cell therapies, gene therapies, and other advanced therapeutics as more of them progress through the pipeline for the treatment of rare, complex, and otherwise challenging diseases and disorders. The second half of this year is shaping up to continue the trend, with several Prescription Drug User Fee Act (PDUFA) dates already slated for the coming months and other companies having recently submitted biologics license applications (BLAs) to the agency or planning resubmissions in the near-term future. With 2025 having recently hit its midway point, the CGTLive® team has highlighted 5 notable therapies to keep an eye on as the remainder of the year unfolds.